Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- (Open, Randomized, Phase II )

NCT05949541 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05949541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05949541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- (Open, Randomized, Phase II )
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
July 26, 2023
Completion date
January 31, 2028
Enrollment
265 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer